PROPEL® Sinus Stent
Approved by the FDA, the PROPEL® sinus stent is clinically proven to improve surgical outcomes for patients who have undergone interventional procedures to address chronic sinusitis.
PROPEL is placed into the patient’s sinus after surgery to keep passageways enlarged, precisely deliver anti-inflammatory medication directly to the sinus tissue, and then dissolve.
PROPEL CANDIDATES
PROPEL was created for patients with chronic sinusitis who have undergone endoscopic sinus surgery.
To know if you are a candidate for PROPEL, an ENT doctor will need to complete a full exam, including medical history, physical exam, possibly a CT scan, and/or other imaging tests.

HOW PROPEL WORKS
The PROPEL implant is carefully inserted into the sinus cavity as the final stage of surgery.
It works like a spring under modest tension to prop open the ethmoid sinus to maintain the surgical opening, making it easier for the patient to breathe and avoid infections.
At the same time, it gradually provides an anti-inflammatory corticosteroid to reduce swelling, prevent nasal polyp formation, and enhance healing.
The implant remains in place for a few weeks but will fully dissolve over time, so there’s no need for it to be removed by the doctor, making postoperative care easier on patients.
BENEFITS
PROPEL has been clinically proven to:
- Improve post-surgical results
- Reduce the need for post-operative intervention, such as revision surgery
- Reduce the need for oral or systemic steroids
- Reduce inflammation
- Reduce the risk of scarring
- Decrease recurrence of polyp formation
POST-OPERATIVE CARE
Always follow your doctor’s instructions. Frequent saline irrigations are important for post-surgical healing.
IMPORTANT SAFETY INFORMATION
The PROPEL sinus implant is intended for use following ethmoid sinus surgery to maintain the sinus opening. PROPEL mini is intended for use following ethmoid or frontal sinus surgery to maintain the sinus opening. These products are intended for use in patients ≥ 18 years of age. These products are not intended for people who are allergic to the drug mometasone furoate (MF) or to certain polymers. Safety and effectiveness of implants in pregnant or nursing females has not been studied. Risks may include pain/pressure, movement of the implant (within or out of the sinus) and possible side effects of the drug. The most common side effects in clinical studies were infection, headache, and nosebleed. For more information on the risks and benefits of PROPEL, please talk to your doctor. The FDA approved labeling can be found at www.PROPELOPENS.com. Rx only.